
Opinion|Videos|January 9, 2025
OlympiA: Adj Olaparib Post (Neo) Adjuvant Chemo in Pts with Germline BRCA1/BRCA2 & High Risk HER2-negative
Panelists discuss the OlympiA trial, evaluating adjuvant olaparib post-neoadjuvant chemotherapy in patients with germline BRCA1/BRCA2 mutations and high-risk HER2-negative breast cancer, and its impact on treatment outcomes.





































